The authors apologize for the written mistakes in the Results section and Tables. Corrections are shown below.
1) P1710, left column, line 1
Incorrect:
and identified 14 mutation carriers
(29.2%).
Correct:
and identified 14 mutation carriers
(30.4%).
2) P1711, left column, line 15
Incorrect:
mutation-positive group
(P=0.018). Exercise-induced bVT
(P=0.043)
and sinus bradycardia
(P=0.021)
were significantly more frequent in the
RYR2
mutation-positive patients. In contrast, atrial arrhythmias were detected at a similar frequency in both groups
(P=0.261).
Correct:
mutation-positive group
(P=0.034). Exercise-induced bVT
(P=0.047)
and sinus bradycardia
(P=0.002)
were significantly more frequent in the
RYR2
mutation-positive patients. In contrast, atrial arrhythmias were detected at a similar frequency in both groups
(P=0.625).
3) P1711, left column, line 21
Incorrect:
Thirty-one
probands of 47 underwent exercise stress tests. The remaining
16
subjects were not examined because of cerebral palsy, hypoxic brain damage at the first attack or diagnosis on other examinations such as Holter monitoring ECG. Thirty probands of
31
developed
Correct:
Thirty-two
probands of 47 underwent exercise stress tests. The remaining
15
subjects were not examined because of cerebral palsy, hypoxic brain damage at the first attack or diagnosis on other examinations such as Holter monitoring ECG. Thirty probands of
32
developed
4) P1711, right column, line 2
Incorrect:
significantly more prevalent
(P=0.027)
in the
RYR2
Correct:
significantly more prevalent
(P=0.015)
in the
RYR2
5) P1711, right column, line 10
Incorrect:
Flecainide was prescribed in
6
RYR2
Correct:
Flecainide was prescribed in
7
RYR2
6) P1711, right column, line 34
Incorrect:
was significantly more prevalent
(P=0.027)
in
RYR2
Correct:
was significantly more prevalent
(P=0.015)
in
RYR2
7) P1712, left column, line 39
Incorrect:
in the
RYR2
mutation-positive group (Table 2;
33.3%
Correct:
in the
RYR2
mutation-positive group (Table 2;
29.6%
8) P1712, left column, line 58
Incorrect:
(P=0.027)
in
RYR2
mutation-positive probands,
Correct:
(P=0.015)
in
RYR2
mutation-positive probands,
9) Page 1710, Table 2
Table 2.
Clinical Characteristics of CPVT Probands and Comparison of
RYR2 Mutation Positive and Negative Groups
| |
Total (n=47) |
RYR2-positive |
RYR2-negative |
P-value |
| CPVT (n=27) |
CPVT (n=20) |
| Male |
19 (40.4) |
11 (40.7) |
8 (40.0) |
NS |
| Mean age at onset (years) |
10.2±7.3 |
8.6±4.7 |
12.6±9.9 |
NS |
| Family history of sudden death |
7 (14.9) |
6 (22.2) |
1 (5.0) |
NS |
| Clinically diagnosed CPVT family members |
9 (19.1) |
8 (29.6) |
1 (5.0) |
0.034 |
| Mean HR (beats/min) |
63±14 |
60±15 |
67±13 |
NS |
| Mean QTc (ms) |
423±29 |
425±20 |
420±39 |
NS |
| More severe symptom |
| Life-threatening arrhythmias |
17 (36.1) |
9 (33.3) |
8 (40.0) |
NS |
| Exercise-induced syncope |
38 (80.9) |
24 (88.9) |
14 (70.0) |
NS |
| Ventricular arrythmia |
| bVT |
17 (36.2) |
13 (48.1) |
4 (20.0) |
0.047 |
| pVT |
31 (66.0) |
19 (70.4) |
12 (60.0) |
NS |
| VF |
16 (34.0) |
8 (29.6) |
8 (40.0) |
NS |
| Atrial arrhythmia |
6 (12.8) |
4 (14.8) |
2 (10.0) |
NS |
| AF |
1 (2.1) |
1 (3.7) |
0 |
NS |
| Afl |
1 (2.1) |
1 (3.7) |
0 |
NS |
| AT |
2 (4.3) |
2 (7.4) |
0 |
NS |
| PSVT |
2 (4.3) |
0 |
2 (10.0) |
NS |
| Sinus bradycardia |
22 (46.8) |
18 (66.7) |
4 (20.0) |
0.002 |
| Exercise-stress test |
31 (64.8) |
|
|
|
| Positive |
30 (63.8) |
19 (70.3) |
11 (55.0) |
NS |
| Negative |
2 (4.3) |
1 (3.7) |
1 (5.0) |
NS |
Data given as mean±SD or n (%). Mean age at onset, mean age at which patients experienced the first symptomatic arrhythmic attack or were recorded as having physical stress-induced ventricular tachycardia. Exercise stress test was considered positive for bigeminal PVCs, PVC couplets, bVT, pVT, or VF. PSVT, paroxysmal supraventricular tachycardia. Other abbreviations as in Table 1.
10) Page 1711, Table 3
Table 3.
Comparison of the Treatment Between
RYR2 Mutation Positive and Negative Probands
| |
Total (n=47) |
RYR2-positive |
RYR2-negative |
P-value |
| CPVT (n=27) |
CPVT (n=20) |
| β-blockers |
43 (91.5) |
27 (100.0) |
16 (80.0) |
0.015 |
| β-blockers only |
27 (57.4) |
16 (59.3) |
11 (55.0) |
NS |
| Flecainide |
9 (19.1) |
7 (25.9) |
2 (10.0) |
NS |
| Verapamil |
9 (19.1) |
6 (22.2) |
3 (15.0) |
NS |
| Verapamil only |
1 (2.2) |
0 (0) |
1 (5.0) |
NS |
| Amiodarone |
1 (2.2) |
0 (0) |
1 (5.0) |
NS |
| Combination |
| β-blockers + verapamil |
5 (10.6) |
4 (14.8) |
1 (5.0) |
NS |
| β-blockers + ICD |
3 (6.4) |
1 (3.7) |
2 (10.0) |
NS |
| β-blockers + flecainide |
3 (6.4) |
3 (11) |
0 (0) |
NS |
| β-blockers + verapamil + ICD |
1 (2.2) |
1 (3.7) |
0 (0) |
NS |
| β-blockers + flecainide + ICD |
3 (6.4) |
2 (7.4) |
1 (5.0) |
NS |
| β-blockers + verapamil + flecainide |
2 (4.3) |
1 (3.7) |
1 (5.0) |
NS |
| β-blockers + verapamil + flecainide + ICD |
1 (2.2) |
1 (3.7) |
0 (0) |
NS |
| ICD |
8 (17.0) |
5 (18.5) |
3 (15.0) |
NS |
| No medication |
2 (4.2) |
0 (0) |
2 (10.0) |
NS |
Data given as n (%). CPVT, catecholaminergic polymorphic ventricular tachycardia. Other abbreviations as in Table 1.
